Share this video  

EHA 2022 | Emerging novel agents for the treatment of mastocytosis

Tracy George, MD, ARUP Laboratories, University of Utah, Salt Lake City, UT comments on the movement from broad, cladribine-based regimens to novel, targeted tyrosine kinase inhibitors (TKIs) such as avapritinib, for the treatment of systemic mastocytosis. Dr George also comments on the future development of antibody-based therapies, emphasizing the importance of more selective agents with fewer side effects. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.


Consultant, Cogent Blueprint

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter